Skip to main content

​
Overview

The MAT/MOUD Tracking module supports medication-assisted treatment workflows for opioid use disorder and other substance use disorders. It provides enrollment management, medication event recording, and monitoring protocol tracking integrated with patient charts.

​
Quick Reference

​
Permissions

​
Workflows

​
1. Create a New Enrollment

  1. Navigate to Clinical > MAT/MOUD Enrollments (/cl/mat)
  2. Click New Enrollment
  3. Fill in required fields:
    • Patient Chart — select the patient
    • Primary Medication — e.g., Buprenorphine/Naloxone, Methadone, Naltrexone
    • Start Date — enrollment start
    • Treatment Phase — Induction, Stabilization, or Maintenance
  4. Optionally link a 42 CFR Part 2 consent record (required for SUD cases)
  5. Click Save

​
2. Record a Medication Event

  1. Open an enrollment from the list
  2. In the Medication Events section, click Record Event
  3. Select event type: Ordered (order placed before prescription), Prescribed, Administered, Dispensed, Held, or Missed
  4. Enter medication name, dose value/unit, and timestamp
  5. Set adherence status (On Time, Late, Missed) if applicable
  6. Click Save

​
3. Schedule and Complete Monitoring

  1. Open an enrollment detail page
  2. In the Monitoring Events section, click Add Monitoring
  3. Select monitoring type: UDS, Hepatic Panel, CBC, or Other
  4. Set Due By date
  5. Click Save
  6. When the monitoring is completed, click Mark Complete on the event row
Overdue items are highlighted in red with an “Overdue” badge.

​
4. Update Treatment Phase

Treatment phases follow the clinical progression:
  • Induction → Stabilization → Maintenance
To update, edit the enrollment and change the treatment phase field.

​
5. End an Enrollment

To complete or discontinue an enrollment:
  1. Edit the enrollment
  2. Set Status to Completed or Discontinued
  3. Enter the End Date
  4. Add discontinuation reason if applicable
  5. Click Save
For SUD-related MAT cases, 42 CFR Part 2 consent must be active before accessing enrollment data. The system enforces this at the database level. If consent is not present, MAT records will not be accessible. The 2024 amendments to 42 CFR Part 2 are now in effect (compliance date: 2026-02-16), and OCR accepts complaints for violations from that date. Under the updated rule, a single consent can cover future TPO disclosures, and HIPAA-covered recipients may redisclose according to HIPAA when disclosure is authorized by that consent. CL-11 consent workflows should be verified for updated single-consent and NPP requirements. Part 2 records still cannot be used in legal/civil proceedings without explicit consent.

​
Settings

  • MAT behavior is governed by module-level CL settings and permission assignments (cl.moud.*).
  • Organization role mapping should be aligned with PF-30 permission governance.
  • Consent enforcement behavior depends on CL-11 consent configuration and active patient consent records.

​
Known Limitations

  • Medication event type availability and workflow sequencing may vary by organization policy.
  • Monitoring protocol templates are limited to configured event types (UDS, hepatic panel, CBC, other).
  • Legal/regulatory workflows are documented guidance and must be validated against active org policy and CL-11 implementation state.

​
Troubleshooting

​
Tips

  • Medication events are sorted newest-first for quick reference
  • Monitoring events show due/overdue status at a glance
  • All MAT data is subject to the same clinical document access controls as the patient chart
  • Specification: specs/cl/specs/CL-21-medication-assisted-treatment-moud-tracking.md
  • Admin Guide: docs/cl/mat-moud-admin-guide.md
  • Regulatory Tracker: docs/compliance/REGULATORY_COMPLIANCE_TRACKER.md